Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

BI-3406

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Boehringer Ingelheim, Novo Nordisk

Drug class:

SOS1 inhibitor

Related drugs:

‹

›

KRAS mutation	Pancreatic Cancer	KRAS mutation	Pancreatic Cancer	BI-3406 Sensitive: D – Preclinical BI-3406 Sensitive : D	BI-3406 Sensitive: D – Preclinical BI-3406 Sensitive : D
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	BI-3406 + MEK inhibitor Sensitive: D – Preclinical BI-3406 + MEK inhibitor Sensitive : D	BI-3406 + MEK inhibitor Sensitive: D – Preclinical BI-3406 + MEK inhibitor Sensitive : D
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	BI-3406 + MEK inhibitor Sensitive: D – Preclinical BI-3406 + MEK inhibitor Sensitive : D	BI-3406 + MEK inhibitor Sensitive: D – Preclinical BI-3406 + MEK inhibitor Sensitive : D
KRAS Y96S	Solid Tumor	KRAS Y96S	Solid Tumor	trametinib + BI-3406 Sensitive: D – Preclinical trametinib + BI-3406 Sensitive : D	trametinib + BI-3406 Sensitive: D – Preclinical trametinib + BI-3406 Sensitive : D
KRAS Y96D	Solid Tumor	KRAS Y96D	Solid Tumor	trametinib + BI-3406 Sensitive: D – Preclinical trametinib + BI-3406 Sensitive : D	trametinib + BI-3406 Sensitive: D – Preclinical trametinib + BI-3406 Sensitive : D
KRAS G12D	Pancreatic Ductal Adenocarcinoma	KRAS G12D	Pancreatic Ductal Adenocarcinoma	trametinib + BI-3406 Sensitive: D – Preclinical trametinib + BI-3406 Sensitive : D	trametinib + BI-3406 Sensitive: D – Preclinical trametinib + BI-3406 Sensitive : D
KRAS G12D	Endometrial Cancer	KRAS G12D	Endometrial Cancer	trametinib + BI-3406 Sensitive: D – Preclinical trametinib + BI-3406 Sensitive : D	trametinib + BI-3406 Sensitive: D – Preclinical trametinib + BI-3406 Sensitive : D